This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • TRastuzumab in HER2-negative Early breast cancer a...
Clinical trial

TRastuzumab in HER2-negative Early breast cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) ("Treat CTC" trial)

Read time: 1 mins
Last updated:13th Jun 2013
To evaluate whether trastuzumab decreases the detection rate of CTC in patients with HER2-negative primary BC by comparing the trastuzumab treated arm to the observation arm.
Category Value
Study start date 2013-06-13

View full details